Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
dacomitinib + gedatolisib
- Development stage
- Phase 1
- Lead developer
- Pfizer
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Dacomitinib is a pan-HER (human epidermal growth factor receptor) tyrosine kinase inhibitor that irreversibly blocks signaling through EGFR, HER2, and HER4. Gedatolisib is a dual inhibitor of phosphatidylinositol-3-kinase (PI3K) and mammalian target of rapamycin (mTOR), targeting all class I isoforms of PI3K as well as mTOR. The combination of dacomitinib and gedatolisib has been investigated in preclinical models and clinical trials for various solid tumors, including head and neck squamous cell carcinoma (HNSCC), non-small cell lung cancer (NSCLC), breast cancer, esophagogastric cancer, and ovarian cancer. The rationale for combining these agents is to simultaneously inhibit two key oncogenic pathways—HER/EGFR signaling via dacomitinib and PI3K/mTOR signaling via gedatolisib—potentially overcoming resistance mechanisms seen with single-agent targeted therapy.
- Other names
- dacomitinib and gedatolisibdacomitinib plus gedatolisib
02
Targets
EGFR (Epidermal growth factor receptor)ERBB2 (Erb-b2 receptor tyrosine kinase 2)ERBB4 (Erb-b2 receptor tyrosine kinase 4)PIK3CA (Phosphoinositide 3-kinase alpha)PIK3CB (Phosphatidylinositol 3-kinase beta subunit)PIK3CG (Phosphatidylinositol 4,5-bisphosphate 3-kinase gamma)PIK3CD (Phosphatidylinositol 3-kinase delta)mTOR (Mammalian target of rapamycin kinase)
Beyond the preview
Go deeper on dacomitinib + gedatolisib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on dacomitinib + gedatolisib.